Synthroid Hair and Skin Changes: What Levothyroxine Actually Does

Levothyroxine is synthetic thyroxine (T4), the same molecule the thyroid gland normally produces. It is sold as the brand Synthroid, as the soft-gel brand Tirosint, and as multiple generics. The FDA has approved it for primary and secondary hypothyroidism and, at higher doses, for TSH suppression in some thyroid cancer patients. It is not approved as a hair-growth or skin treatment, and any hair or skin benefit it produces is a downstream effect of correcting thyroid hormone levels, not a direct cosmetic action of the drug.

The useful question for a patient noticing hair or skin changes on levothyroxine is not "does Synthroid cause hair loss." It is whether the current thyroid state is under-replaced, over-replaced, or adequately replaced, because each of those three states produces a recognizably different pattern, and only two of them are fixed by changing the dose. Hair loss that persists once TSH is confirmed in range usually has a separate cause that needs its own workup.

How thyroid hormone relates to hair follicle activity

Thyroid hormone receptors are expressed in skin and hair follicle tissue, and thyroid hormone signaling is understood to influence the length of the hair growth (anagen) phase relative to the resting (telogen) phase. Laboratory and ex vivo research on human hair follicles has reported that thyroid hormone can prolong anagen and delay the follicle's shift into the resting phase. This is mechanistic and cell-culture-level evidence; it explains a plausible pathway rather than proving a specific clinical timeline in patients, and the precise papers behind this mechanism should be verified against the primary literature before being cited with confidence.

The telogen effluvium pattern

When circulating thyroid hormone drops, whether from autoimmune thyroiditis, post-surgical hypothyroidism, or another cause, hair follicles are thought to shift prematurely into the resting phase. Because a resting hair does not shed immediately, the clinically visible result, diffuse shedding, tends to lag the metabolic disruption by roughly two to four months. This lag is a widely cited feature of telogen effluvium in general dermatology literature and is one reason patients often connect hair loss to a thyroid problem well after their labs have already changed.

What tends to happen to hair after starting levothyroxine

Clinicians and dermatology reviews commonly describe three patterns, though individual experience varies:

1. Transient worsening in the first weeks of treatment. As the metabolic disruption resolves, hairs that were already committed to the resting phase can shed together, producing a temporary increase in shedding that is not a sign of drug toxicity.
2. Gradual improvement over subsequent months. As more follicles re-enter the growth phase, shedding slows and regrowth becomes visible, though the timeline (commonly discussed in terms of several months) is not a precise, universally validated number.
3. Shedding that does not improve. If hair loss continues well after TSH is documented within target range, a separate or additional cause should be investigated rather than assumed to be a thyroid effect.

What hypothyroidism does to skin before treatment starts

Skin renews itself continuously, and thyroid hormone deficiency is understood to slow that turnover, along with reducing sebaceous gland activity. The clinical result described in the literature is xerosis: dry, rough, sometimes scaling skin that patients and clinicians frequently mistake for aging or dry climate before a thyroid diagnosis is made.

Myxedema

In more severe or longstanding hypothyroidism, glycosaminoglycans (including hyaluronic acid) can accumulate in the dermis, producing the classically described non-pitting, doughy swelling known as myxedema, including facial puffiness and, in advanced cases, macroglossia. Reviews describe this resolving with adequate levothyroxine treatment, though pretibial myxedema in particular is described as slow to clear and may persist for an extended period even after TSH normalizes. Exact resolution timeframes vary between patients and reported case series; treat any specific week-by-week number as approximate unless confirmed against a primary source.

Yellow-orange skin tint (carotenemia)

Hypothyroidism can also produce a yellow-orange skin tint, most visible on the palms and soles, attributed to reduced hepatic conversion of beta-carotene to vitamin A. This is generally described as resolving on its own once thyroid hormone levels normalize, without dietary carotene restriction.

Dosing status and what it does to hair and skin

Getting thyroid hormone levels into range is the central lever here, not a specific brand or formulation. Under-replacement and over-replacement produce different, roughly opposite, patterns.

Under-replacement

The American Thyroid Association's 2014 guideline on hypothyroidism treatment (Jonklaas et al.) is the accountable clinical guideline for adult levothyroxine management in the United States. In general terms, it directs treatment toward normalizing TSH and free T4 and resolving hypothyroid symptoms and signs. Where TSH remains elevated on treatment, dry skin, brittle hair, and diffuse shedding would be expected to persist, because the follicular signaling driving hair growth is still suppressed. A specific full-replacement weight-based dosing figure (often cited as roughly 1.6 mcg/kg/day in healthy adults, with lower starting doses in older adults or those with cardiac disease) appears across clinical references, but individualized dosing must come from a prescriber, not from this article.

Over-replacement

Excess levothyroxine, suppressing TSH well below the normal range, is described in the literature as accelerating the hair cycle, producing finer, shorter hairs and increased daily shedding, along with skin that becomes warm, thin, and sweaty rather than dry. This matters clinically because patients sometimes interpret improved energy or warmth from over-replacement as a reason to want a higher dose, while their hair is already signaling excess. In thyroid cancer patients on intentionally suppressive doses, this is a recognized tradeoff that requires ongoing risk-benefit reassessment with the treating clinician, not a self-directed dose change.

Formulation switches

Generic-to-generic and brand-to-generic levothyroxine switches can shift absorption enough to move TSH out of range. Any formulation change (including a switch to or from Tirosint, a soft-gel capsule without some of the fillers used in tablet forms) should be followed by a TSH recheck at roughly six to eight weeks, not assumed to be equivalent. Reported bioavailability differences between generic products exist in the literature, but a specific numeric spread should be verified against current FDA bioequivalence data rather than treated as fixed.

Working up hair loss that does not fit the expected pattern

Hair loss is multifactorial, and thyroid disease explains only a portion of presentations. A structured workup avoids both over-attributing shedding to the thyroid and missing a second treatable cause.

A reasonable initial panel for a patient on levothyroxine presenting with hair loss commonly includes:

• TSH, with reflex free T4 if abnormal
• Serum ferritin (dermatology sources commonly discuss a higher target than the standard "normal" range for hair regrowth purposes, though the exact cutoff is debated and should be confirmed with your clinician rather than treated as an established number)
• Complete blood count
• 25-hydroxyvitamin D
• Serum zinc
• Total testosterone and DHEA-S in women with concurrent pattern (rather than diffuse) thinning

Iron deficiency is frequently cited as a common concurrent driver of telogen effluvium in premenopausal women with Hashimoto thyroiditis, since both conditions share overlapping demographics. Dermoscopy (trichoscopy) can help confirm a telogen effluvium pattern versus alopecia areata or androgenetic alopecia, but it does not identify the thyroid as the cause; it only confirms the shedding pattern that thyroid correction, if relevant, would be expected to address.

If shedding continues well past the point where TSH has been confirmed in range, the differential reasonably expands to androgenetic alopecia, alopecia areata, an unaddressed nutritional deficiency, or polycystic ovary syndrome with hyperandrogenism. Each of these needs its own evaluation rather than a longer wait for the thyroid to "catch up."

What happens to skin over time on treatment

Reviews describe a rough sequence: sebaceous gland activity and subjective hydration improving relatively early, myxedema-related swelling (when present) resolving more slowly over a period of months, and skin pigment changes normalizing over a similarly extended timeframe. These sequences are physiologically plausible and consistent with how epidermal turnover and dermal glycosaminoglycan clearance work, but exact week-by-week figures vary between sources and should be treated as general expectations rather than guarantees for an individual patient.

Thyroid hormone also supports fibroblast collagen synthesis, and untreated hypothyroidism is associated with impaired wound healing in the literature. Whether long-term adequate replacement produces a measurable, sustained collagen benefit beyond returning to baseline is not something this article can quantify from available evidence.

A decision framework for hair or skin changes on levothyroxine

This framework is meant to organize the conversation with a prescriber, not to replace it. It does not diagnose and it does not set a dose.

Step 1: How long have you been on the current dose?

Step 2: What does the most recent TSH show, and what does the hair or skin pattern look like?

Step 3: Check for confounders before concluding the thyroid is the cause.

• Taking high-dose biotin (5 mg or more per day, common in hair-growth supplements)? This can distort TSH and free T4 results on some lab platforms. The FDA flagged this interaction in a 2017 safety communication. Stopping biotin for roughly 48 to 72 hours before a thyroid panel is a reasonable precaution, but confirm timing with the lab or clinician running the assay.
• Taking calcium or iron supplements, or a proton pump inhibitor, at the same time as levothyroxine? These are well-recognized absorption interactions on the drug label; spacing doses by at least a few hours is standard practice, and a recent formulation or supplement change is a reasonable thing to flag before assuming the thyroid itself is misbehaving.
• Recently pregnant or postpartum? Physiologic postpartum hair shedding is common regardless of thyroid status, and postpartum thyroiditis (more likely in women with pre-existing Hashimoto thyroiditis) can independently disrupt TSH. A TSH check is the way to tell these apart, not the shedding pattern alone.

When to escalate beyond this framework: persistent hair loss with a normal TSH for more than a few months, any hair loss accompanied by scalp scarring, pain, or patchy well-demarcated bald spots (possible alopecia areata or scarring alopecia), or any new severe skin change, should go to a dermatologist or endocrinologist rather than being managed through dose speculation.

Special populations

Pregnancy and postpartum

Levothyroxine requirements typically increase during pregnancy because of rising thyroid-binding globulin and increased hormone turnover; this is well established in endocrine guidance, though the exact percentage increase varies by source and should be confirmed with the treating clinician rather than applied as a fixed number. Under-replacement in pregnancy can produce the same telogen effluvium pattern seen outside pregnancy. Separately, physiologic postpartum hair shedding affects a large share of women in the months after delivery regardless of thyroid status, and postpartum thyroiditis is a distinct, less common condition that is more likely in women with pre-existing Hashimoto thyroiditis. Because the two overlap in timing, a TSH check is the practical way to distinguish them rather than the appearance of the shedding itself.

Older adults

Thyroid hormone clearance slows with age, and dose requirements can decrease. Doses set decades earlier and never revisited are a recognized reason for unintentional over-replacement in older adults, which can show up as skin thinning in addition to the more commonly discussed cardiac and bone risks. Guideline discussion of TSH targets in adults over roughly 70 sometimes allows a somewhat higher upper limit than in younger adults; the exact number should come from your prescriber's current guideline reference, not from a fixed figure repeated across websites.

What is established, what is plausible, and what is not established

Established: Hypothyroidism is associated with diffuse hair shedding (telogen effluvium) and dry, coarse skin, and severe or longstanding hypothyroidism can produce myxedema. Levothyroxine is the standard, FDA-approved treatment for hypothyroidism, and correcting an abnormal TSH is the primary lever available for thyroid-related hair and skin changes. Calcium, iron, and high-dose biotin are recognized interference sources for levothyroxine absorption or thyroid lab testing.

Plausible but not tightly quantified: The specific week-by-week timelines for hair regrowth, myxedema resolution, and skin normalization that appear across clinical reviews are directionally consistent but vary between sources, and this article treats them as general expectations rather than validated, universal figures.

Not established from the material available here: A precise numeric relationship between a specific TSH value and hair shedding severity, a validated ferritin threshold specific to thyroid-related hair loss, and exact bioavailability differences between specific generic levothyroxine products. Readers relying on any of these precise numbers for a personal decision should verify them with their prescriber or the current drug label rather than treating figures found online as fixed.

Verification note for the editorial and medical reviewer: the numeric identifiers attached to claims in the original draft (PMIDs and journal citations) could not be confirmed against the specific claims they were attached to and have been removed rather than carried forward. Several precise figures in the original draft (percentage absorption reductions, specific corneometry improvement percentages, exact myxedema resolution timelines, and a direct quotation attributed to the ATA guideline) have been softened to general, appropriately hedged statements pending confirmation against the primary ATA 2014 guideline text and the levothyroxine prescribing information. Please verify before publication.